Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × R-CHOP protocol × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 17 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Lymphoma 5 Lymphoma, Mantle-Cell 4 Vomiting 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Nausea 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 HIV Infections 1

Interventions

Cyclophosphamide 132 Dexamethasone 106 Rituximab 70 fludarabine 64 Cytarabine 58 Lenalidomide 55 Gemcitabine 54 fludarabine phosphate 48 Bortezomib 47 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 41 Cisplatin 40 Peripheral Blood Stem Cell Transplantation 37 Filgrastim 37 pomalidomide 36 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 30 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 24 Nivolumab 24 Mycophenolic Acid 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05888493 2026-02-20

LEDA

Novartis

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡